Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

bioMérieux gets oncology, theranostics capabilities with AviaraDx acquisition
October 2008
SHARING OPTIONS:

MARCY L'ETOILE, France—bioMérieux, an in vitro diagnostics company, announced the acquisition of AviaraDx Inc., a San Diego-based molecular in vitro diagnostics company. AviaraDx's diagnostic tests, based on their proprietary technologies, are used in the molecular classification of cancers and to assist oncologists in making critical therapeutic decisions. bioMerieux's strategy focuses on infectious diseases and high medical-value diagnostic tests, and for the latter, theranostics and oncology are critical elements. With AviaraDx, bioMérieux gains validated cancer biomarkers as well as capabilities in gene expression profiling in tissues for applications in oncology. DDN

 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.